Axsome Therapeutics, Inc. Overview
Pro stress-test →Axsome Therapeutics is a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders in the United States. Unlike many biotechs, it is not a one-drug outfit with three products on the market now and more to come. The company demonstrated strong momentum with full year 2025 net product revenue of $638.5 million, representing 66% annual growth.
Strategic Profile
Pro stress-test →Axsome's stable $800M+ revenue base caps downside and supports ongoing operations, shifting risk from existential to executional and enabling pipeline-driven upside. Auvelity (for major depressive disorder) is the big draw with sales up 69% in Q3, with management thinking peak sales could be $2 billion or so, about four times current run-rate basis. Two drugs are likely to get FDA approval in 2026: AXS-12 targeting narcolepsy ($500 million opportunity) and AXS-05 for Alzheimer's agitation with potential into the $1.5 billion range or more (approval likely in first half of 2026).
Competitive Landscape
Pro stress-test →Axsome competes in the CNS disorder treatment market with products addressing depression, Alzheimer's disease, narcolepsy, fibromyalgia, and sleep disorders. Key competitors include larger pharmaceutical companies developing similar CNS therapies, though Axsome's differentiated mechanism-of-action portfolio and commercial execution distinguish its positioning in the growing neuroscience market.
Industry Context
Axsome Therapeutics, Inc. operates in Biopharmaceutical (CNS Therapeutics).
Key facts
Founded: 2012 · Headquarters: New York, US · Employees: 683 · Revenue: $638.5M (2025) · Market cap: $37B